Item 7.01 Regulation FD Disclosure.

Registrant has been engaged in completing a restatement of its financial reports contained in its previous filings on Form 10-Q for the periods ending June 30, 2019 and September 30, 2019 and completing the audit of its financial statements for the year ended December 31, 2019 to include its Form 10-K for the year ended December 31, 2019. The restatements and audit have been difficult but are in the final stages and the Form 10-K for the year ended December 31, 2019 is nearly complete. The filing must complete final review of our independent accounting firm and will then be filed. Filing is expected before year end. The quarterly Form 10-Q filings for the First, Second and Third Quarters of 2019 are prepared and will be completed and reviewed as soon as the final audit results for the year ended December 31, 2019 are approved. All future filings with the SEC will be made on a timely basis, including the Form 10-K for the year ended December 31, 2020.

The delinquent filings for 2019 resulted from a number of unexpected and unavoidable issues, including:

1. Our previous independent accounting firm advised us in January 2020 that it


    did not have the capacity to undertake the audit for 2019 and resigned the
    engagement. This resignation was unexpected and there was no prior indication
    of any issues. The resignation was reported on Form 8-K filed on January 13,
    2020.

2. On January 29, 2020, we engaged our current independent accounting firm,

Rosenberg Rich Baker Berman P.A. ("RRBB") as reported on Form 8-K filed on
    January 31, 2010. RRBB had no prior information regarding our company and
    undertook a complete review of prior filings and financial reports, resulting
    in a determination that certain items related to the acquisition of the
    CareClix operating software in April 2019 and the issuance of convertible
    notes in April and May 2019 had been reported incorrectly. This determination
    required us to retain an outside consulting group to complete a valuation of
    the assets acquired as a business combination and to restate the reporting of
    the convertible notes to reflect a derivative feature of those notes.

3. The COVID-19 pandemic significantly affected the business and operations of


    the company as it moved into the telemedicine market as a result of the
    acquisition of the CareClix telemedicine software. On March 30, 2020, the
    company filed a Form 8-K report advising that we would be taking advantage of
    the extended filing period contained in SEC Release No. 34-88465.

4. In April 2020, the SEC included the Company shares in a temporary trading


    suspension of a number of public telemedicine companies, to which the company
    responded by a Form 8-K filing dated April 14, 2020. The temporary trading
    suspension expired after two weeks and subsequently, the company requested and
    received from the SEC a letter advising that there was no investigation of the
    company underway. The suspension did, however, result in the automatic
    termination of the trading of the company shares on the OTC Markets, which has
    affected additional fund-raising efforts of the company. In turn, the company
    had difficulty expanding staff to meet demands of the business and could not
    expand staff to assist with the financial reporting or expansion of the
    business.

© Edgar Online, source Glimpses